GlassScriptPhysician profile
Anoop Thakur
NPI 1861433211
$11,847.86
in general payments reported to CMS, 2019-2025
25 companies · $8,408 in 2025
The $8,408 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $277 · 2021: $132 · 2022: $131 · 2023: $42.97 · 2024: $1,653 · 2025: $8,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $9,731 · Food and Beverage: $261 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $9,731.25 |
| Food and Beverage | $261.03 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $9,731.25 | 2024-2025 | Venclose Maven Catheter |
| Otsuka America Pharmaceutical, INC. | $343.90 | 2019-2025 | Abilify Asimtufii, Rexulti |
| Sunovion Pharmaceuticals INC. | $239.01 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $157.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.67 | 2019-2020 | |
| Lundbeck LLC | $133.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $125.80 | 2019-2025 | |
| Allergan, INC. | $123.21 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.91 | 2021-2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $96.28 | 2021-2022 | |
| Tris Pharma INC | $83.71 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $75.83 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Ironshore Pharmaceuticals INC. | $74.52 | 2019-2020 | |
| Shire North American Group INC | $69.37 | 2019 | |
| Corium, LLC | $65.56 | 2022-2023 | Azstarys |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $59.73 | 2019-2025 | |
| Alkermes, INC. | $44.71 | 2022-2025 | Aristada, Lybalvi |
| Jazz Pharmaceuticals INC. | $33.30 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $31.01 | 2025 | Rejoyn |
| E.R. Squibb & Sons, L.L.C. | $30.51 | 2025 | Cobenfy |
| Neuronetics, INC. | $20.44 | 2020 | |
| Vertical Pharmaceuticals, LLC | $18.66 | 2019 | |
| Neos Therapeutics, LP | $17.31 | 2019 | |
| Abbvie INC. | $14.82 | 2022 | |
| Avanir Pharmaceuticals, INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anoop Thakur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.